- Home
- PNR vs GMAB Comparison
PNR vs GMAB Comparison
Compare PNR & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNR
- GMAB
- Stock Information
- Founded
- PNR 1966
- GMAB 1999
- Country
- PNR United Kingdom
- GMAB Denmark
- Employees
- PNR N/A
- GMAB N/A
- Industry
- PNR Industrial Machinery/Components
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- PNR Industrials
- GMAB Health Care
- Exchange
- PNR Nasdaq
- GMAB Nasdaq
- Market Cap
- PNR 15.8B
- GMAB 13.7B
- IPO Year
- PNR N/A
- GMAB N/A
- Fundamental
- Price
- PNR $107.38
- GMAB $21.45
- Analyst Decision
- PNR Buy
- GMAB Buy
- Analyst Count
- PNR 16
- GMAB 8
- Target Price
- PNR $107.87
- GMAB $37.80
- AVG Volume (30 Days)
- PNR 1.4M
- GMAB 1.6M
- Earning Date
- PNR 07-22-2025
- GMAB 08-07-2025
- Dividend Yield
- PNR 0.93%
- GMAB N/A
- EPS Growth
- PNR 2.96
- GMAB 276.80
- EPS
- PNR 3.87
- GMAB 18.36
- Revenue
- PNR $4,076,000,000.00
- GMAB $3,230,902,140.00
- Revenue This Year
- PNR $2.18
- GMAB $747.74
- Revenue Next Year
- PNR $4.10
- GMAB $14.81
- P/E Ratio
- PNR $27.78
- GMAB $1.17
- Revenue Growth
- PNR N/A
- GMAB 25.43
- 52 Week Low
- PNR $74.25
- GMAB $17.24
- 52 Week High
- PNR $110.71
- GMAB $28.56
- Technical
- Relative Strength Index (RSI)
- PNR 67.20
- GMAB 53.47
- Support Level
- PNR $104.63
- GMAB $20.23
- Resistance Level
- PNR $108.59
- GMAB $21.90
- Average True Range (ATR)
- PNR 1.81
- GMAB 0.35
- MACD
- PNR 0.36
- GMAB 0.06
- Stochastic Oscillator
- PNR 87.53
- GMAB 73.52
About PNR Pentair plc.
Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Pentair's business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.1 billion in revenue in 2024.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.